Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

CONNECTA Therapeutics closes €3.1 million financing led by Clave Capital to advance clinical development of CTH120 for Fragile X syndrome.

PRIVATESep 10, 2026•about 3 hours ago

Amount Raised

€3.1 Million

Round Type

Seed

BarcelonaBiotechnologyHealth CareTherapeutics

Investors

Prous Institute For Biomedical ResearchCdti InnvierteInvereadyClave Capital

Description

CONNECTA Therapeutics has closed a €3.1 million financing led by new investor Clave Capital and supported by existing investors. The funds will accelerate the Phase IIa clinical trial of CTH120 in adult males with Fragile X syndrome. This funding marks a significant milestone for the company as it aims to improve outcomes for patients. The trial is expected to provide important data in mid-2027.

Company Information

Company

CONNECTA Therapeutics

Location

Barcelona, Catalonia, Spain

About

CONNECTA Therapeutics is a clinical-stage biotech company leveraging its small-molecule neuroplasticity modulation platform to address unmet medical needs in central nervous system (CNS) disorders. Its lead program, CTH120, is a potential first-in-class disease-modifying treatment for Fragile X syndrome (FXS), a rare and currently untreatable neurodevelopmental disorder that strongly impairs cognition and behavior. Backed by strong preclinical research and clinical safety data, CONNECTA is advancing its program to provide improved outcomes for patients.

Don't miss CONNECTA Therapeutics's next move

Get an email the moment CONNECTA Therapeutics raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for CONNECTA Therapeutics's next move

See what Strategic adds

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

CONNECTA Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.